The Food and Drug Administration has approved secnidazole for the treatment of bacterial vaginosis (BV) and trichomoniasis in patients aged 12 years and older.
The antimicrobial agent, marketed as Solosec, was first approved in 2017 as a treatment for BV in adult women. In 2021, it was approved for the treatment of trichomoniasis in adult men and women.
Lupin Pharmaceuticals, which manufactures the drug, announced the expanded approval for adolescents in a news release.
The medication is meant to be taken as a single dose. It comes in a packet that should be sprinkled onto applesauce, yogurt, or pudding and consumed without chewing or crunching.
The treatment option may help “address gaps in care related to adherence,” said Tom Merriam, an executive director with Lupin.
Bacterial vaginosis is a common vaginal infection. Trichomoniasis is the most common nonviral, curable STI in the United States. Sexual partners of patients with trichomoniasis can be treated at the same time.
Vulvovaginal candidiasis is one of the possible side effects of secnidazole treatment, the drug’s label notes.
This story originally appeared on MDedge.com, part of the Medscape Professional Network.
Source: Read Full Article